141 related articles for article (PubMed ID: 36069226)
1. STAT5b is a marker of poor prognosis, rather than a therapeutic target in glioblastomas.
Dubois N; Berendsen S; Tan K; Schoysmans L; Spliet W; Seute T; Bours V; Robe PA
Int J Oncol; 2022 Oct; 61(4):. PubMed ID: 36069226
[TBL] [Abstract][Full Text] [Related]
2. DARPP32, STAT5 and STAT3 mRNA expression ratios in glioblastomas are associated with patient outcome.
Televantou D; Karkavelas G; Hytiroglou P; Lampaki S; Iliadis G; Selviaridis P; Polyzoidis KS; Fountzilas G; Kotoula V
Pathol Oncol Res; 2013 Apr; 19(2):329-43. PubMed ID: 23250732
[TBL] [Abstract][Full Text] [Related]
3. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
4. TROY signals through JAK1-STAT3 to promote glioblastoma cell migration and resistance.
Ding Z; Kloss JM; Tuncali S; Tran NL; Loftus JC
Neoplasia; 2020 Sep; 22(9):352-364. PubMed ID: 32629176
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of HOXC10 promotes glioblastoma cell progression to a poor prognosis via the PI3K/AKT signalling pathway.
Guan Y; He Y; Lv S; Hou X; Li L; Song J
J Drug Target; 2019 Jan; 27(1):60-66. PubMed ID: 29768063
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of transcription factor STAT5b suppresses proliferation, induces G1 cell cycle arrest and reduces tumor cell invasion in human glioblastoma multiforme cells.
Liang QC; Xiong H; Zhao ZW; Jia D; Li WX; Qin HZ; Deng JP; Gao L; Zhang H; Gao GD
Cancer Lett; 2009 Jan; 273(1):164-71. PubMed ID: 18793823
[TBL] [Abstract][Full Text] [Related]
7. Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma.
Liang Y; Bollen AW; Aldape KD; Gupta N
BMC Cancer; 2006 Apr; 6():97. PubMed ID: 16623952
[TBL] [Abstract][Full Text] [Related]
8. Nuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter.
Latha K; Li M; Chumbalkar V; Gururaj A; Hwang Y; Dakeng S; Sawaya R; Aldape K; Cavenee WK; Bogler O; Furnari FB
Int J Cancer; 2013 Feb; 132(3):509-20. PubMed ID: 22729867
[TBL] [Abstract][Full Text] [Related]
9. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
[TBL] [Abstract][Full Text] [Related]
10. A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells.
Ahmed EM; Bandopadhyay G; Coyle B; Grabowska A
Cell Oncol (Dordr); 2018 Jun; 41(3):319-328. PubMed ID: 29492900
[TBL] [Abstract][Full Text] [Related]
11. Integrative analysis of cell adhesion molecules in glioblastoma identified prostaglandin F2 receptor inhibitor (PTGFRN) as an essential gene.
Mala U; Baral TK; Somasundaram K
BMC Cancer; 2022 Jun; 22(1):642. PubMed ID: 35690717
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of CD97 confers an invasive phenotype in glioblastoma cells and is associated with decreased survival of glioblastoma patients.
Safaee M; Clark AJ; Oh MC; Ivan ME; Bloch O; Kaur G; Sun MZ; Kim JM; Oh T; Berger MS; Parsa AT
PLoS One; 2013; 8(4):e62765. PubMed ID: 23658650
[TBL] [Abstract][Full Text] [Related]
13. The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells.
Johannessen TC; Prestegarden L; Grudic A; Hegi ME; Tysnes BB; Bjerkvig R
Neuro Oncol; 2013 Mar; 15(3):269-78. PubMed ID: 23258843
[TBL] [Abstract][Full Text] [Related]
14. MPC1 deletion is associated with poor prognosis and temozolomide resistance in glioblastoma.
Chai Y; Wang C; Liu W; Fan Y; Zhang Y
J Neurooncol; 2019 Sep; 144(2):293-301. PubMed ID: 31236818
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-128-3p Enhances the Chemosensitivity of Temozolomide in Glioblastoma by Targeting c-Met and EMT.
Zhao C; Guo R; Guan F; Ma S; Li M; Wu J; Liu X; Li H; Yang B
Sci Rep; 2020 Jun; 10(1):9471. PubMed ID: 32528036
[TBL] [Abstract][Full Text] [Related]
16. Sohlh1 suppresses glioblastoma cell proliferation, migration, and invasion by inhibition of Wnt/β-catenin signaling.
Liu X; Gao Q; Zhao N; Zhang X; Cui W; Sun J; Fu J; Hao J
Mol Carcinog; 2018 Apr; 57(4):494-502. PubMed ID: 29240260
[TBL] [Abstract][Full Text] [Related]
17. Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastoma.
Zhang Y; Kim J; Mueller AC; Dey B; Yang Y; Lee DH; Hachmann J; Finderle S; Park DM; Christensen J; Schiff D; Purow B; Dutta A; Abounader R
Cell Death Differ; 2014 May; 21(5):720-34. PubMed ID: 24440911
[TBL] [Abstract][Full Text] [Related]
18. Expression and prognostic significance of TCTN1 in human glioblastoma.
Meng D; Chen Y; Zhao Y; Wang J; Yun D; Yang S; Chen J; Chen H; Lu D
J Transl Med; 2014 Oct; 12():288. PubMed ID: 25304031
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme.
Han J; Puri RK
J Neurooncol; 2018 Feb; 136(3):463-474. PubMed ID: 29168083
[TBL] [Abstract][Full Text] [Related]
20. EGFRvIII-Stat5 Signaling Enhances Glioblastoma Cell Migration and Survival.
Roos A; Dhruv HD; Peng S; Inge LJ; Tuncali S; Pineda M; Millard N; Mayo Z; Eschbacher JM; Loftus JC; Winkles JA; Tran NL
Mol Cancer Res; 2018 Jul; 16(7):1185-1195. PubMed ID: 29724813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
